• Drug Store News, Friday, October 7, 2011 12:45 PM

German drug maker Merck KGaA will collaborate with Japanese drug maker Ono Pharmaceutical to develop oral therapies for cancer and multiple sclerosis, Merck KGaA said.

The Merck Serono division of Merck KGaA, a separate company from U.S.-based Merck that operates as EMD in the United States and Canada, signed an agreement with Ono that gives it worldwide exclusive rights for development and commercialization of the MS drug ONO-4641 outside of Japan, Korea and Taiwan. Another license agreement gives Ono Japanese co-development and marketing rights to Stimuvax, an investigative cancer immunotherapy that stimulates the body's immune system to target cancer cells.

Read the whole story at Drug Store News »